Rochelle Collins, DO
Family Medicine · Bloomfield, CTNPI 1205847241
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- GSK$424
- Abbott$390
- Lilly USA, LLC$349
- AbbVie$265
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,274100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $1,280 |
| AstraZeneca | 41 | $1,123 |
| GSK | 14 | $424 |
| Abbott | 18 | $390 |
| Lilly USA, LLC | 17 | $349 |
| AbbVie | 14 | $265 |
| Pfizer | 17 | $259 |
| Exact Sciences | 10 | $240 |
| Astellas Pharma US Inc | 10 | $235 |
| QOL Medical, LLC | 5 | $152 |
| Lundbeck LLC | 7 | $151 |
| Neurocrine Biosciences, Inc. | 2 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $135 |
| Sanofi-aventis U.S. LLC | 6 | $114 |
| Actelion Pharmaceuticals US, Inc. | 3 | $104 |
| Antares Pharma, Inc. | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| Sumitomo Pharma America, Inc. | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $70 |
| Kowa Pharmaceuticals America, Inc. | 3 | $61 |
| Johnson & Johnson | 3 | $61 |
| Currax Pharmaceuticals LLC | 4 | $58 |
| Boehringer Ingelheim | 2 | $47 |
| Ardelyx, Inc. | 2 | $44 |
| Corcept Therapeutics | 2 | $41 |
| Baxter Healthcare | 1 | $35 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Shield Therapeutics Inc | 1 | $23 |
| Bayer | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Bausch Health US, LLC | 1 | $19 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,278 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $107,876 |
| FarxigaDapagliflozin Propanediol | 56 | $75,184 |
| MounjaroTirzepatide | 37 | $42,397 |
| TrulicityDulaglutide | 11 | $23,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $20,829 |
| JardianceEmpagliflozin | 15 | $19,683 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $11,560 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,313 |
| Levemir FlexpenInsulin Detemir | 11 | $1,735 |
| Lidocaine | 21 | $1,346 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,117 |
| Nebivolol Hcl | 25 | $1,047 |
| Atorvastatin Calcium | 155 | $1,042 |
| Amlodipine Besylate | 201 | $937 |
| Rosuvastatin Calcium | 105 | $918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,280 | $107,87669 claims |
| AstraZenecaFarxiga | $1,123 | $75,18456 claims |
| Lilly USA, LLCMounjaro, Trulicity | $349 | $66,14548 claims |
| GSKTrelegy Ellipta | $424 | $20,82916 claims |
| Boehringer IngelheimJardiance | $47 | $19,68315 claims |
| MerckJanumet | $16 | $11,56017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Bloomfield
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
- Sanjeev RaoBridgeport$27K
- Michael BeyVernon Rockville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.